Advertisement

Topics

Bluebird prices gene therapy at 1.575 million euros over five years

04:02 EDT 14 Jun 2019 | Reuters

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

Original Article: Bluebird prices gene therapy at 1.575 million euros over five years

NEXT ARTICLE

More From BioPortfolio on "Bluebird prices gene therapy at 1.575 million euros over five years"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...